Moderna starts testing its vaccine among teens

Moderna (MRNA.US) announced today that it has begun a phase 2/3 clinical trial designed to position its COVID-19 vaccine for use in children aged 12 to less than 18 before the start of the 2021-22 school year. The drugmaker  has dosed the first participant in a study expected to enroll 3,000 healthy people. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA). "Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," said Chief Executive Officer Stéphane Bancel. Meanwhile US FDA will meet on December 17th to discuss whether to recommend the use of Moderna's vaccine.
Yesterday Moderna received a downgrade from Needham from ‘Buy’ to ‘Hold’ rating. Analysts believe that Moderna's stock is fully valued after capturing an eightfold gain this year.

Moderna (MRNA.US) stock is testing major support at $150.00 which coincides with 50 SMA (green line) and upward trendline. As long as the price sits above it, the continuation of a upward trend looks probable. The nearest key resistance lies at the $178.68 level. However if sellers will manage to break below the support zone, a downward impulse towards $129.12 could be launched. Source: xStation5

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.